Home › Funds › MAK CAPITAL ONE LLC › AUTL
MAK CAPITAL ONE LLC position in AUTL
AUTOLUS THERAPEUTICS LTD · Health Care
MAK CAPITAL ONE LLC reported holding 33,621,487 shares of AUTL (AUTOLUS THERAPEUTICS LTD) in its Q2 2026 13F filing — a position valued at US$53.8M, representing 7.54% of its reported portfolio and ranking #6 among its reported holdings. MAK CAPITAL ONE LLC has disclosed AUTL holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MAK CAPITAL ONE LLC's AUTL position evolved
MAK CAPITAL ONE LLC first disclosed a stake in AUTL in Q2 2025 at 16,955,098 shares (US$38.7M). The position peaked in Q4 2025 at 30,005,343 shares, worth US$59.7M. Across 5 filings, MAK CAPITAL ONE LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 33,621,487 shares valued at US$53.8M. Notable position changes include a 53% increase in Q3 2025 (shares rose 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 16.96M | $38.66M | New |
| Q3 2025 | 26.02M | $42.41M | Add |
| Q4 2025 | 30.01M | $59.71M | Add |
| Q1 2026 | 33.62M | $46.40M | Add |
| Q2 2026 | 33.62M | $53.79M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AUTL and 13F data
AUTL (AUTOLUS THERAPEUTICS LTD) is a Health Care company. 18 other funds we track also report a position in AUTL — the largest reported positions include Syncona Portfolio Ltd (US$26.6M), ARMISTICE CAPITAL, LLC (US$24.0M), Tetragon Partners GP Ltd (US$15.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AUTL
- Syncona Portfolio Ltd 16.64M sh · $26.63M · Q2 2026
- ARMISTICE CAPITAL, LLC 15.00M sh · $24.00M · Q2 2026
- Tetragon Partners GP Ltd 9.50M sh · $15.20M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.45M sh · $7.12M · Q2 2026
More on MAK CAPITAL ONE LLC
FAQ
How long has MAK CAPITAL ONE LLC held AUTL?
MAK CAPITAL ONE LLC has disclosed AUTL holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is MAK CAPITAL ONE LLC's current position in AUTL?
As of Q2 2026, MAK CAPITAL ONE LLC holds 33.62M shares of AUTL (AUTOLUS THERAPEUTICS LTD), valued at $53.79M, representing 7.54% of its reported portfolio and ranking #6.
Has MAK CAPITAL ONE LLC been buying or selling AUTL?
In the latest 13F filing (Q2 2026), MAK CAPITAL ONE LLC held unchanged its position in AUTL. The position peaked in Q4 2025 at 30.01M shares.
Which other funds hold AUTL?
Other major institutional holders of AUTL include Syncona Portfolio Ltd, ARMISTICE CAPITAL, LLC, Tetragon Partners GP Ltd, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.